Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA, Genesis Genome Ink Distribution Agreement for Malaysia

NEW YORK (GenomeWeb) – OncoDNA today announced a distribution deal with Malaysian oncology firm Genesis Genome to bring affordable theranostic analysis to that country. 

Under the terms of the deal, Genesis Genome has selected OncoDNA as its exclusive supplier of clinical grade molecular theranostics and will make available to Malaysian physicians OncoDNA's OncoDeep DX and OncoDeep Clinical cancer panels combined with its Package Plus, enabling clinically relevant interpretations of patients' tumors using the OncoShare web platform. 

OncoDeep DX comprises 65 genes while the OncoDeep Clinical cancer panel comprises 409 genes. Package Plus is made up of immunohistochemistry and other tests to analyze the presence of key proteins and activity and translocations. 

Financial and other terms of the deal were not disclosed. 

The agreement is the 16th reached by OncoDNA, it said. In recent months, the Belgium firm inked similar deals with the Eone-Diagnomics Genome Center, Progenetics, and BioSequence

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.